5
CCME Global Ltd
GENESISIBRCINDIALTD NSE
CCME Global Ltd
HealthcareNSE: GENESISIBRCINDIALTD BSE: CCME Biotechnology
Key Fundamentals
MicrocapBiotechnologyHealthcareMarket Cap
₹493 Cr
Volatility
Moderate
P/E Ratio
-682.8
EBITDA
₹0.20 Cr
Return on Equity
-0.35%
Debt to Equity
0
Book Value
₹8.86
52W High
₹184.9
52W Low
₹24.55
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view CCME Global Ltd insights
45 extracted metrics + investor summaries across FY14–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Company is almost debt free.
- Promoter holding has increased by 62.8% over last quarter.
Weaknesses
3- Stock is trading at 12.3 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.66% over last 3 years.
Growth Rate
Revenue Growth
-
Net Income Growth
-120.00% ↘
Cash Flow Change
112.53% ↗
ROE
-3.00% ↘
ROCE
-
EBITDA Margin (Avg.)
-
Quarterly Results
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 3.67 | 0 | 0 | 0 | 0 | 0 | 0.04 |
| Expenses | 0.05 | 0.06 | 0.02 | 0.02 | 3.69 | 0.1 | 0.02 | 0.03 | 0.02 | 0.12 | 0.06 | 0.03 | 0.54 |
| Operating Profit | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.1 | 3.65 | -0.03 | -0.02 | -0.12 | -0.06 | -0.03 | -0.5 |
| OPM % | — | — | — | — | — | — | 99.46% | — | — | — | — | — | -1250% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.1 | 3.65 | -0.03 | -0.02 | -0.12 | -0.06 | -0.03 | -0.5 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.1 | 3.65 | -0.03 | -0.02 | -0.12 | -0.06 | -0.03 | -0.5 |
| EPS in Rs | -0.04 | -0.05 | -0.02 | -0.02 | -2.84 | -0.08 | 2.81 | -0.02 | -0.02 | -0.09 | -0.05 | -0.02 | -0.11 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.78 | 0 | 0 | 0.29 | 0.05 | 0 | 0 | 0 | 0 | 0 | 0 | 0.04 |
| Expenses | 0.93 | 0.07 | 0.07 | 0.49 | 0.1 | 0.1 | 0.12 | 0.12 | 0.14 | 3.8 | 0.17 | 0.75 |
| Operating Profit | -0.15 | -0.07 | -0.07 | -0.2 | -0.05 | -0.1 | -0.12 | -0.12 | -0.14 | -3.8 | -0.17 | -0.71 |
| OPM % | -19.23% | — | — | -68.97% | -100% | — | — | — | — | — | 95.37% | -1775% |
| Other Income | -0.09 | 0.42 | 0.07 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.67 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.45 | 0.35 | 0 | -0.2 | -0.05 | -0.1 | -0.12 | -0.12 | -0.14 | -3.8 | 3.5 | -0.71 |
| Tax % | 0% | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -0.44 | 0.35 | 0 | -0.2 | -0.05 | -0.1 | -0.12 | -0.12 | -0.14 | -3.8 | 3.5 | -0.71 |
| EPS in Rs | -0.62 | 0.36 | 0 | -0.15 | -0.04 | -0.08 | -0.09 | -0.09 | -0.11 | -2.92 | 2.69 | -0.16 |
| Div. Payout % | 0% | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.12 | 9.74 | 10 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 45.25 |
| Reserves | -3.7 | -3.35 | -3.35 | -3.55 | -3.7 | -3.8 | -3.92 | -4.04 | -4.17 | -7.97 | -4.47 | -5.18 |
| Borrowings | 0.17 | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0.93 | 0.51 | 0.03 | 0.07 | 0.08 | 0.12 | 0.12 | 0.13 | 0.14 | 0.18 | 0.3 | 5.24 |
| Total Liabilities | 4.52 | 7.1 | 6.68 | 9.52 | 9.38 | 9.32 | 9.2 | 9.09 | 8.97 | 5.21 | 8.83 | 45.31 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 4.66 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 4.52 | 7.1 | 6.68 | 4.86 | 9.38 | 9.32 | 9.2 | 9.09 | 8.97 | 5.21 | 8.83 | 45.31 |
| Total Assets | 4.52 | 7.1 | 6.68 | 9.52 | 9.38 | 9.32 | 9.2 | 9.09 | 8.97 | 5.21 | 8.83 | 45.31 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -4.86 | -2.64 | -0.25 | 1.68 | -4.69 | 0.01 | -0.12 | -0.12 | -0.09 | 0 | 0 | 5.1 |
| Investing | 0.77 | 0 | 0 | -4.66 | 4.66 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing | 4.1 | 2.62 | 0.26 | 3 | 0 | 0 | 0.12 | 0.12 | 0.09 | 0 | 0 | 32.25 |
| Net Cash Flow | 0.01 | -0.02 | 0.01 | 0.02 | -0.03 | 0.01 | 0 | 0 | -0.01 | 0 | 0 | 37.35 |
| Free Cash Flow | -4.09 | -2.64 | -0.25 | 1.68 | -4.69 | 0.01 | -0.12 | -0.12 | -0.09 | 0 | 0 | 5.1 |
| CFO/OP | 3,240 | 3,771 | 357 | -840 | 9,380 | -10 | 100 | 100 | 64 | 0 | 0 | -718 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 229 | — | — | 62.93 | 292 | — | — | — | — | — | — | 0 |
| Inventory Days | 0 | — | — | 0 | — | — | — | — | — | — | — | — |
| Cash Conversion Cycle | 229 | — | — | 62.93 | 292 | — | — | — | — | — | — | 0 |
| Working Capital Days | 1,586 | — | — | 5,991 | 67,890 | — | — | — | — | — | — | 24,729 |
| ROCE % | -16.62% | 6.88% | 0% | -2.48% | -0.53% | -1.08% | -1.31% | -1.33% | -1.57% | -54.83% | 51.62% | -2.92% |
Documents
1
Intimation About Receipt Of Listing Approval For 32250000 Equity Shares Allotted On March 26, 2026
30 Apr - BSE approved listing of 3,22,50,000 equity shares issued at par on preferential basis. 30 Apr - BSE approved listing of 3,22,50,000 equity shares issued at par on preferential basis.
2
Intimation About Receipt Of Listing Approval For 32250000 Equity Shares Allotted On March 26, 2026
30 Apr - BSE approved listing of 3,22,50,000 equity shares issued at par on preferential basis. 30 Apr - BSE approved listing of 3,22,50,000 equity shares issued at par on preferential basis.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
17 Apr - Company confirms it is not a large corporate under SEBI circular as of 31 March 2026. 17 Apr - Company confirms it is not a large corporate under SEBI circular as of 31 March 2026.
4
Board Meeting Outcome for Outcome Of Board Meeting For Appointment Of Company Secretary, Compliance Officer And KMP. Also For Situation Of Corporate Office And Keeping Books Of Accounts At The Place Other Than Registered Office.
8 Apr - Board appointed Ms. Garima Garg as Company Secretary and Compliance Officer from April 8, 2026; books moved to Mumbai office. 8 Apr - Board appointed Ms. Garima Garg as Company Secretary and Compliance Officer from April 8, 2026; books moved to Mumbai office.
5
Announcement under Regulation 30 (LODR)-Change in Corporate Office Address
8 Apr - Ms. Garima Garg appointed Company Secretary and Compliance Officer effective April 8, 2026. 8 Apr - Ms. Garima Garg appointed Company Secretary and Compliance Officer effective April 8, 2026.
Frequently Asked Questions about CCME Global Ltd
What does CCME Global Ltd do?
Incorporated in 1992, Genesis IBRC India Ltd (Formerly SSK Lifestyles Limited) is in the business of Biotechnology.
Where is CCME Global Ltd (514336) listed?
CCME Global Ltd is listed on the Indian stock exchanges. It is listed on NSE: GENESISIBRCINDIALTD and BSE: CCME. You can view its live share price, financials, and ratios on Tapetide.
Which sector does CCME Global Ltd belong to?
CCME Global Ltd operates in the Healthcare sector within the Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of CCME Global Ltd?
CCME Global Ltd has a market capitalisation of approximately ₹493.27 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of CCME Global Ltd?
The Price-to-Earnings (PE) ratio of CCME Global Ltd is -682.80. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of CCME Global Ltd?
Over the past 52 weeks, CCME Global Ltd has traded between a low of ₹24.55 and a high of ₹184.9. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of CCME Global Ltd?
CCME Global Ltd has a Return on Equity (ROE) of -0.35%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research CCME Global Ltd on Tapetide?
On Tapetide, you can view CCME Global Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1992, Genesis IBRC India Ltd (Formerly SSK Lifestyles Limited) is in the business of Biotechnology.